COMPANY PROFILE

MEPSGEN

Explore full profile

Bio-drug development and research services through human long-term modeling chip platforms

Seoul, South KoreaFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MEPSGEN

Mepsgen is a leading company of micro engineered physiological system.

We specialize in developing and producing 3D cell culture organ-on-a-chip platform and nanomedicine technology. Our products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of development.

The company carries out fundamental biological research in an environment equipped with an organ-level function of connected human tissues instead of in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify in a physiologically relevant environment in order to validate the discovery of new biological mechanisms.

Mepsgen holds many patents, patents pending, and numerous IP licenses in the Bio Technology field. Mepsgen which is founded in 2019 is a startup company in Seoul, South Korea. For more information visit www.mepsgen.com

[ Industry ] Drug Discovery Drug Delivery Biotechnology

[ Technology ] NanoMedicine Human Organ-on-a-Chip

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Seoul, South Korea
Employees: 31
Open positions: 17
Dealroom signal: 48.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Microfluidics, Spinout, Techbio, organ-on-chip, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES C✓Equity / VC	Nov 2024	$33M	$132M	Undisclosed	↗
SERIES B✓Equity / VC	Jul 2022	$14M	$58M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

MEPSGEN website traffic

Latest recorded traffic for MEPSGEN is 7.6K monthly website visits, up 68.9% over the last three months. MEPSGEN's team declined 3.1% over the past year.

Latest monthly visits7.6K 3-month web change+68.9% 1-year team growth-3.1%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

( )Seoul, South Korea · Other · Jul 10, 2026 [ ]Beobwon-ro 11-gil, Munjeong 1(il)-dong, Songpa-gu, Seoul, 05854, South Korea · Other · Jun 22, 2026 BIO KOREA International convention 2023Beobwon-ro 11-gil, Munjeong 1(il)-dong, Songpa-gu, Seoul, 05854, South Korea · Other · Jun 22, 2026 Korea BioChip Society Annual Fall Meeting 2023: BioChips Beyond Fundamental ResearchBeobwon-ro 11-gil, Munjeong 1(il)-dong, Songpa-gu, Seoul, 05854, South Korea · Other · Jun 22, 2026 BIX - BIOPLUS INTERPHEX KOREA 2023Beobwon-ro 11-gil, Munjeong 1(il)-dong, Songpa-gu, Seoul, 05854, South Korea · Other · Jun 22, 2026 BIO JAPAN 2023Yokohama, Japan, Eastern Asia, Asia · Other · Jun 19, 2026

6 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QTQuris TechnologiesAn artificial intelligence innovator that is disrupting the drug development process	Tel Aviv-Yafo, Israel	Operational	36	$38M	$95M
BIBiomimXDeveloping beating organs-on-chip platforms as in vitro pre-clinical models to improve the drug development process	Milan, Italy	Operational
BSBi/ond SolutionsEmpowers biological innovation by engineering hardware solutions for cell-based assays	Delft, Netherlands	Closed
MIMimetasDeveloping physiologically relevant 3D human disease models and partnering with global pharmaceutical companies to create therapies for untreatable diseases	Oegstgeest, Netherlands	Acquired
OKOkomeraOkomera is pioneering automation and miniaturization of personalized tumor biopsy studies	Paris, France	Operational
FIFinnadvanceDeveloping microfluidic organ-on-chips for pharmaceutical drug research and development.	Oulu, Finland	Operational
ATARTIC TechnologiesDevelops microscale fluid control solutions inspired by nature for advanced cell culture platforms	Eindhoven, Netherlands	Operational
REReact4lifeOrgan-on-chip solution to improve the development of new drugs and reduce the use of animals for trials	Genoa, Italy	Operational